Victory Capital Management Inc Palatin Technologies Inc Transaction History

Victory Capital Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$0.27 - $0.5 $53 - $99	-198 Reduced 0.64%	30,605 $9,000
Q1 2022 May 04, 2022	SELL	$0.37 - $0.54 $307 - $448	-831 Reduced 2.63%	30,803 $12,000
Q4 2021 Feb 07, 2022	SELL	$0.34 - $0.86 $272 - $689	-802 Reduced 2.47%	31,634 $16,000
Q3 2021 Nov 02, 2021	SELL	$0.44 - $0.63 $720 - $1,031	-1,638 Reduced 4.81%	32,436 $14,000
Q2 2021 Aug 03, 2021	SELL	$0.48 - $0.72 $506 - $760	-1,056 Reduced 3.01%	34,074 $21,000
Q1 2021 May 04, 2021	SELL	$0.68 - $1.25 $729 - $1,341	-1,073 Reduced 2.96%	35,130 $24,000
Q4 2020 Feb 01, 2021	BUY	$0.38 - $0.78 $738 - $1,516	1,944 Added 5.67%	36,203 $24,000
Q3 2020 Nov 09, 2020	SELL	$0.47 - $0.64 $928 - $1,264	-1,975 Reduced 5.45%	34,259 $16,000
Q2 2020 Aug 07, 2020	SELL	$0.41 - $0.73 $448 - $798	-1,094 Reduced 2.93%	36,234 $19,000
Q1 2020 May 04, 2020	SELL	$0.36 - $0.79 $296 - $650	-824 Reduced 2.16%	37,328 $16,000
Q4 2019 Feb 04, 2020	BUY	$0.75 - $0.89 $2,552 - $3,028	3,403 Added 9.79%	38,152 $25,000
Q3 2019 Nov 12, 2019	BUY	$0.78 - $1.09 $27,104 - $37,876	34,749 New	34,749 $32,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $10.4M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.